Concord Biotech invests $1,500 in Stellon Biotech, acquiring 75% via 15M shares at $0.0001 each to boost U.S. operations.

• Stellon, a Delaware-based pre-revenue company formed in Dec 2024, supports Concord's product commercialization.
• Investment funds marketing and expansion of pharmaceutical products in the U.S. market through Stellon.
• Concord's ownership ensures strategic control over Stellon's growth and operational decisions.